T

    Traws Pharma Inc (TRAW)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.59
    +0.00 (+0.36%)

    Market Cap: $9.07M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +271.45%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.63-215.0%
    60d ago$-0.36-80.0%
    30d ago$-0.36-80.0%
    7d ago$-0.36-80.0%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.12 - $-0.12
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.20---
    Jun 26
    		$-0.16$-0.22+27.27%Beat+0.0%
    Mar 26
    		$-0.52$-0.56+7.14%Beat-124.9%
    Dec 25
    		$-0.55$-0.54-2.67%Miss-102.1%
    Sep 25
    		$-0.34N/A+96.29%Beat+96.1%
    Jun 25
    		$-0.16N/A+98.17%Beat+99.9%
    Mar 25
    		$2.09$-0.27+888.68%Beat+141.8%
    Dec 24
    		$26.60$-0.25+10740.00%Beat+14100.0%
    Sep 24
    		$-8.81$-6.25-40.96%Miss-53.2%
    Jun 24
    		$-121.75$-6.25-1848.00%Miss-2335.0%
    Mar 24
    		$-5.00$-6.33+21.01%Beat+28.6%
    Dec 23
    		$-0.19$-0.25+24.00%Beat+26.9%
    Sep 23
    		$-5.75$-7.25+20.69%Beat+11.5%
    Jun 23
    		$-5.00$-7.81+35.98%Beat-5.3%
    Mar 23
    		$-7.00$-7.44+5.91%Beat-40.0%
    Dec 22
    		$-0.26$-0.26+0.00%Beat-52.9%
    Sep 22
    		$-6.50$-5.31-22.41%Miss-18.2%
    Jun 22
    		$-4.75$-4.94+3.85%Beat+29.6%
    Mar 22
    		$-5.00$-4.69-6.61%Miss-1566.7%
    Dec 21
    		$-0.17$-0.17+0.00%Beat+98.5%
    Sep 21
    		$-5.50$-8.17+32.68%Beat+51.1%
    Jun 21
    		$-6.75$-7.12+5.20%Beat+55.0%
    Mar 21
    		$-0.30$-0.45+33.33%Beat+97.3%
    Dec 20
    		$-11.25$-13.12+14.25%Beat-1078.3%
    Sep 20
    		$-11.25$-12.50+10.00%Beat+96.0%
    Jun 20
    		$-15.00$-11.25-33.33%Miss+93.3%
    Mar 20
    		$-11.25$-20.62+45.44%Beat+97.7%
    Dec 19
    		$1.15$-0.07+1742.86%Beat+217.3%
    Sep 19
    		$-281.25$-255.00-10.29%Miss+20.2%
    Jun 19
    		$-225.00$-330.00+31.82%Beat+42.9%
    Mar 19
    		$-483.75$-388.12-24.64%Miss-9385.3%
    Dec 18
    		$-0.98$-0.97-1.03%Miss+100.0%
    Sep 18
    		$-352.50$-435.00+18.97%Beat+91.2%
    Jun 18
    		$-393.75$-431.25+8.70%Beat+75.9%
    Mar 18
    		$-5.10$-0.39-1207.69%Miss+99.9%
    Dec 17
    		$-3318.75$-3867.19+14.18%Beat-614483.3%
    Sep 17
    		$-3993.75$-3895.31-2.53%Miss+10.1%
    Jun 17
    		$-1631.25N/A+59.91%Beat-
    Mar 17
    		$-6918.75$-5400.00-28.13%Miss-
    Dec 16
    		$-0.54N/A+96.40%Beat-
    Sep 16
    		$-4443.75$-4612.50+3.66%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.38EV/EBITDA0.33x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-433.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.93xQuick Ratio0.93x
    Trading Statistics
    Beta1.56Avg Volume102.17K
    52-Week High$3.2752-Week Low$0.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.56
    SMA 20$0.56
    SMA 50$0.62
    SMA 200$1.46
    EMA 10$0.57
    EMA 20$0.57
    EMA 50$0.70
    EMA 200$1.31

    MACD

    Line: -0.01Signal: -0.03Hist: 0.02

    ADX

    ADX: 20.9+DI: 26.8-DI: 21.0

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down16.0
    PSAR$0.54

    Bollinger Bands

    Upper Band$0.61
    Lower Band$0.51
    %B Position1852%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    51.0

    Momentum Oscillators

    Stoch %K68.8
    Stoch %D70.0
    Williams %R-28.7
    ROC (10d)9.6%
    Momentum0.05
    CCI (20d)105.4
    MFI (14d)59.2

    Volatility Measures

    ATR (14d)$0.04(6.8%)
    StdDev (20d)0.03
    Hist Vol87.3%(High)

    Volume Flow

    VWAP$0.59
    OBV117.6M
    AD Line-69.1M
    CMF (20d)-0.134

    Volume Metrics

    Avg Vol (20d)102.4K
    Vol Ratio0.5x
    VWMA (20d)$0.56

    Pivot Points

    R3$0.62
    R2$0.61
    R1$0.60
    Pivot Point$0.59
    S1$0.58
    S2$0.57
    S3$0.56

    Advanced Oscillators

    TSI-7.82
    Ultimate Osc49.3
    KST-20.09

    Financial Data

    QuarterJun 2027Mar 2027Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    Total Revenue$0$0$0$2.73M$57,000$2.62M$57,000$57,000$56,000$57,000$57,000$56,000
    Cost of Revenue$0$0$0$0$0N/A$0$0$0$2,000$2,000$4,000
    Gross Profit$0$0$0$2.73M$57,000$2.62M$57,000$57,000$56,000$55,000$55,000$56,000
    Operating Expenses$3.17M$6.95M$4.05M$3.98M$5.26M$-116,601,000$8.59M$123.41M$5.27M$8.59M$8.59M$5.27M
    R&D$1.10M$4.91M$2.31M$2.29M$2.51M$-116,310,000$5.11M$121.43M$1.91M$5.11M$5.11M$1.91M
    SG&A$3.48M$2.03M$1.74M$1.69M$2.75M$-291,000$3.48M$1.98M$3.36M$3.48M$3.48M$3.36M
    Operating Income$-3,175,000$-6,946,000$-4,055,000$-1,249,000$-5,203,000$119.22M$-8,536,000$-123,348,000$-5,212,000$-8,536,000$-8,536,000$-5,212,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$159,000$3,000$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,960,000$-7,105,000$-4,058,000$-1,103,000$21.31M$145.56M$-8,536,000$-123,348,000$-4,983,000$-8,475,000$-8,475,000$-4,983,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,054,000$-7,107,000$-3,962,000$-915,000$21.49M$145.77M$-8,475,000$-123,143,000$-4,983,000$-8,475,000$-8,475,000$-4,983,000
    EBITDA$-2,916,000$-7,061,000$-4,043,000$-1,102,000$21.31M$145.56M$-8,534,000$-123,344,000$-4,979,000$-8,473,000$-8,473,000$-5,208,000
    EBIT$-2,960,000$-7,105,000$-4,058,000$-1,103,000$21.31M$145.56M$-8,536,000$-123,348,000$-4,983,000$-8,475,000$-8,475,000$-5,212,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRAW

    News

    H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1

    H.C. Wainwright has reiterated a Neutral rating and $1.00 price target for Traws Pharma Inc. following its Q2 2026 update. The company is working to resubmit an updated toxicology package to the MHRA and resolve a U.S. clinical hold, as its TXM drug candidate is currently unable to proceed to a Phase 2a study. Traws Pharma ended Q2 with $5.0 million in cash and is partially relying on anticipated ATM proceeds to fund operations into Q1 2027.

    Investing.com•8/19/26•
    Somewhat-Bearish

    H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1

    H.C. Wainwright has reiterated its Hold rating for Traws Pharma (TRAW.US) and maintained its target price at $1. This indicates the analyst firm sees no immediate significant upside or downside for the stock based on current information.

    Moomoo•8/19/26•
    Neutral

    H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1 By Investing.com

    H.C. Wainwright has reiterated a Neutral rating and a $1.00 price target for Traws Pharma (NASDAQ:TRAW) following the company's Q2 2026 update. Traws Pharma is working to resubmit an updated toxicology package to the MHRA and resolve a U.S. clinical hold by year-end, as its TXM drug candidate remains stalled. Despite a significant stock decline, InvestingPro suggests the stock is undervalued, though investor confidence relies on regulatory acceptance and a clear capital path.

    Investing.com Nigeria•8/19/26•
    Somewhat-Bearish

    TRAW Reiterated by HC Wainwright & Co. -- Maintains Price Target at $1.00

    HC Wainwright & Co. has reiterated a Neutral rating for Traws Pharma Inc (TRAW), maintaining a price target of $1.00. Despite a GF Value™ indicating the stock is significantly undervalued at $13.05 compared to its current price of $0.54, the company's low GF Score™ of 40/100, particularly in profitability and growth, suggests caution for investors. The biotechnology firm is in a clinical stage, focusing on respiratory viral diseases, and analysts' cautious stance reflects concerns about its growth prospects in a competitive market.

    GuruFocus•8/18/26•
    Somewhat-Bearish

    H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1

    H.C. Wainwright has reiterated a Neutral rating and a $1.00 price target on Traws Pharma (NASDAQ:TRAW) following the company's Q2 2026 update. The company is working to resubmit an updated toxicology package to the MHRA and resolve a U.S. clinical hold, as its TXM drug candidate remains unable to enter a planned Phase 2a study. Traws Pharma ended Q2 2026 with $5.0 million in cash and is relying on ATM proceeds to fund operations into Q1 2027, with its stock having declined significantly due to previous setbacks.

    Investing.com•8/18/26•
    Somewhat-Bearish

    Frequently Asked Questions About TRAW

    Does TRAW pay dividends?
    Traws Pharma Inc (TRAW) does not currently pay a regular dividend.
    What is TRAW's market cap?
    Traws Pharma Inc (TRAW) has a market capitalization of $9.07M with a current stock price of $0.59.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In